Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 977-987

  Balint, Joseph P ^a   Gabitzsch, Elizabeth S ^a   Rice, Adrian ^a   Latchman, Yvette ^a   Xu, Younong ^b   Messerschmidt, Gerald L ^a   Chaudhry, Arvind ^c   Morse, Michael A ^d   Jones, Frank R ^a  

^a Etubics Corporation   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c Medical Oncology Associates   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ad5 E1 , E2b CEA(6D); Colorectal cancer; Immunotherapy; Phase 1 2 trial

Indexed keywords

ADENOVIRUS SEROTYPE 5[E1 E2B]CARCINOEMBRYONIC ANTIGEN (6D) VACCINE; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; HLA A2 ANTIGEN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; AD5(E1-,E2B-)-CEA(6D) VACCINE; CAP1-6D; GAMMA INTERFERON; OLIGOPEPTIDE; VIRUS PROTEIN;

ADULT; AGED; ANOREXIA; ANTIBODY TITER; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; EFFECTOR CELL; FEVER; FLOW CYTOMETRY; FLU LIKE SYNDROME; HEADACHE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE REACTION; LONG TERM SURVIVAL; METASTATIC COLORECTAL CANCER; NAUSEA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ADENOVIRIDAE; CELL CULTURE; CLINICAL TRIAL; COLORECTAL NEOPLASMS; CYTOTOXICITY; FEMALE; FOLLOW UP; GENE DELETION; GENETICS; IMMUNIZATION; IMMUNOLOGY; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SURVIVAL; T LYMPHOCYTE SUBPOPULATION;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ADENOVIRUS E2 PROTEINS; ADULT; AGED; CANCER VACCINES; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OLIGOPEPTIDES; SEQUENCE DELETION; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84937970482     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1706-4     Document Type: Article

References (44)

1. Vergati M, Intrivici C, Huen N-Y, Schlom J, Tsang KY (2010) Strategies for cancer vaccine development. J Biomed Biotechnol. doi:10.1155/2010/596432
2. Palena C, Schlom J (2010) Vaccines against human carcinomas: Strategies to improve antitumor immune responses. J Biomed Biotechnol. doi:10.1155/2010/380697
3. Schlom J (2012) Therapeutic cancer vaccines: Current status and moving forward. J Natl Cancer Inst 104:599–613
4. Tatsis N, Ertl HC (2004) Adenoviruses as vaccine vectors. Mol Ther 10:616–629
5. Bangari DS, Mittal SK (2006) Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24:849–862
6. Campos SK, Barry MA (2007) Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther 7:189–204
7. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6:1574–1583
8. Barouch DH, Kikc SV, Weverling GJ et al (2011) International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203–5209
9. Amalfitano A, Chamberlain JS (1997) Isolation and characterization of packaging cell lines that coexpress the adenovirus E1, DNA polymerase, and preterminal proteins: Implications for gene therapy. Gene Ther 4:258–263
10. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 72:926–933
11. Hartigan-O’Connor D, Amalfitano A, Chamberlain JS (1999) Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J Virol 73:7835–7841
12. Seregin SS, Amalfitano A (2009) Overcoming pre-existing adenovirus immunity by genetic engineering of adenovirus based vectors. Expert Opin Biol Ther 9:1521–1531
13. Osada T, Yang XY, Hartman ZC et al (2009) Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. Cancer Gene Ther 16:673–682
14. Gabitzsch ES, Xu Y, Balint JP Jr, Hartman ZC, Lyerly HK, Jones FR (2010) Anti-tumor immunity despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. Cancer Immunol Immunother 59:1131–1135
15. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Gayle RB, Amalfitano A, Jones FR (2009) A preliminary and comparative evaluation of a novel Ad5 [E1-, E2b-] recombinant based vaccine used to induce cell mediated immune responses. Immunol Lett 122:44–51
16. Gabitzsch ES, Yu X, Yoshida LH, Balint J, Amalfitano A, Jones FR (2009) Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27:6394–6398
17. Gabitzsch ES, Xu Y, Balcaitis S, Balint JP Jr, Jones FR (2011) An Ad5 [E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice. Cancer Gene Ther 18:326–335
18. Gabitzsch ES, Xu Y, Balint JP Jr, Balcaitis S, Sanders-Beer B, Jones FR (2011) Induction and comparison of SIV immunity in Ad5 Naïve and Ad5 immune non-human primates using an Ad5 [E1-, E2b-] based vaccine. Vaccine 29:8101–8107
19. Jones FR, Gabitzsch ES, Xu Y et al (2011) Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine. Vaccine 29:7020–7026
20. Gabitzsch ES, Jones FR (2011) New recombinant Ad5 vector overcomes Ad5 immunity allowing for multiple safe, homologous immunizations. J Clin Cell Immunol S4:001. doi:10.4172/2155-9899.S4-001
21. Gabitzsch ES, Balint JP Jr, Xu Y et al (2012) Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform. Vaccine 30:7265–7270
22. Wieking BG, Vermeer DW, Spanos WC et al (2012) A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther 19:667–674
23. Morse MM, Chaudhry A, Gabitzsch ES et al (2013) Novel adenoviral vector induces T cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients. Cancer Immunol Immunother 62:1293–1301
24. Thompson JA, Grunert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives. J Clin Lab Anal 5:344–366
25. Hammarstrom S (1999) The carcinoembryonic antigen (CEA) family: Structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 9:67–81
26. Berinstein NL (2002) Carcinoembryonic antigen as a target for therapeutic anticancer vaccines: A review. J Clin Oncol 20:2197–2207
27. Cheever MA, Allison JP, Ferris AS et al (2009) The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337
28. Gameiro SR, Jammeh ML, Hodge JW (2013) Cancer vaccines targeting carcinoembryonic antigen: State-of-the-art and future promise. Expert Rev Vaccines 12:617–629
29. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J (1997) Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 57:4570–4577
30. Tangri S, Ishioka GY, Huang X et al (2001) Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild type peptide. J Exp Med 194:833–846
31. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
32. CTEP Cancer Therapy Evaluation Program (2010) CTCAE and CTC website http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 10 Feb 2012
33. Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M (2000) Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240:143–155
34. Shafer-Weaver K, Sayers T, Strobl S et al (2003) The Granzyme B ELISPOT assay: An alternative to the 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med 1:14–23
35. Hobeika AC, Clay TM, Mosca PJ, Lyerly HK, Morse MA (2001) Quantitating therapeutically relevant T-cell responses to cancer vaccines. Crit Rev Immunol 21:287–297
36. Hobeika AC, Morse MA, Osada T et al (2005) Enumerating antigen-specific T-cell responses in peripheral blood: A comparison of peptide MHC tetramer, ELISpot, and intracellular cytokine analysis. J Immunother 28:63–72
37. Cory AH, Owen TC, Barltrop JA, Cory JG (1991) Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Comm 3:207–212
38. Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048
39. Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765
40. Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664
41. Small EJ, Schellhammer PF, Higano CS et al (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractoryÂprostate cancer. J Clin Oncol 24:3089–3094
42. Higano CS, Schellhammer PF, Small EJ et al (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670–3679
43. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
44. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804–811